News

Laurent Pharmaceuticals Completes Patients Enrollment in Phase 2 Study of LAU-7b for the Treatment of COVID-19

20 May 2021

Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing the first-in-class pro-resolving drug LAU-7b, today announces that it has completed the enrollment...

Read More

Laurent Pharmaceuticals Provides Clinical Development Update

8 April 2021

Announces Positive Outcome of Pre-Planned Interim DSMB Safety Review and Futility Analysis for Phase 2 RESOLUTION Study in Hospitalized COVID-19 PatientsCompletes...

Read More

EVENTS

Laurent Pharma to participate to BIO International Convention, June 5-8, 2023, Boston, MA

read more
Laurent Pharma to participate to BIO International Convention, June 13-16, 2022 – San Diego, CA
read more
Laurent Pharma to participate to BIO-Europe Spring, March 28-31, 2022
read more
Laurent Pharma to participate to BiotechGate, February 7-9, 2022
read more
Laurent Pharma to participate to Biotech Showcase, January 9-11 and 17-19, 2022
Laurent Pharma to participate to H.C. Wainwright 23rd Annual Global Investment Conference,
September 13-15, 2021
read more